Epidermolysis Bullosa Market Set for Significant Upswing During the Forecast Period (2025-2034) Amid Rising Therapeutic Advancements | DelveInsight
The growth of the epidermolysis bullosa market is expected to be mainly driven by increasing prevalence, patient awareness, label expansion of approved therapies, high cost of therapies, and robust clinical pipeline, including D-Fi/FCX-007 (Castle Creek Biosciences), EBESANAR (RHEACELL and AOP Health), Redasemtide (SHIONOGI/StemRIM), KB803 (Krystal Biotech), AGLE-102 (Aegle Therapeutics), AC-203 (TWi Biotechnology), and others in the coming years.
LAS VEGAS, March 17, 2026 /PRNewswire/ -- Recently published Epidermolysis Bullosa Market Insights report includes a comprehensive understanding of current treatment practices, epidermolysis bullosa emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Epidermolysis Bullosa Market Summary
Discover what is the projected size of the epidermolysis bullosa market by 2036 @ https://www.delveinsight.com/sample-request/epidermolysis-bullosa-market
Key Factors Driving the Growth of the Epidermolysis Bullosa Market
Sadaf Javed, Manager of Forecasting and Analytics at DelveInsight, said that stem cell-based therapies are becoming increasingly important, especially for previously incurable diseases. Due to the special immunomodulatory and anti-inflammatory properties, ABCB5+ mesenchymal stromal cells (ABCB5+ MSCs) represent a new, promising therapeutic approach for various chronic inflammatory diseases, including epidermolysis bullosa.
Epidermolysis Bullosa Market Analysis
Epidermolysis Bullosa Competitive Landscape
Some of the epidermolysis bullosa drugs under development include D-Fi/FCX-007 (Castle Creek Biosciences), EBESANAR (RHEACELL and AOP Health), Redasemtide (SHIONOGI/StemRIM), KB803 (Krystal Biotech), AGLE-102 (Aegle Therapeutics), AC-203 (TWi Biotechnology), and others.
Castle Creek Biosciences' D-Fi, also referred to as FCX-007 (dabocemagene autoficel), is an autologous gene-therapy candidate being developed for the treatment of DEB. It is made from a patient's own dermal fibroblasts, which are genetically engineered using a self-inactivating lentiviral vector carrying the COL7A1 gene, enabling the cells to produce type VII collagen. The therapy is delivered through intradermal injections into the superficial papillary dermis of chronic wounds, where the introduced COL7 protein can help form anchoring fibrils in the skin. The FDA has granted D-Fi Orphan Drug Designation for both DEB and RDEB, as well as RPDD, Fast Track, and RMAT designations specifically for RDEB.
RHEACELL and AOP Health's EBESANAR is a systemic treatment intended for individuals with RDEB and JEB. It is administered every two months via intravenous infusion and aims to improve skin lesions, lower overall disease burden, and prevent ongoing tissue damage. A Phase III clinical trial is currently underway in the United States and Europe, with top-line data expected in late 2025 and a European marketing authorization submission planned for Q1 2026.
SHIONOGI/StemRIM's Redasemtide is a regenerative therapy in development that promotes tissue repair without relying on living cells. It has received Orphan Drug Designation for DEB from the MHLW.
TWi Biotechnology's AC-203 is a proprietary topical version of AC-201, which inhibits caspase-1 activity and reduces production of the cytokine IL-1β by blocking NLRP3 inflammasome activation. Suppression of this pathway and subsequent IL-1β release is effective across several conditions, including arthritis, gout, and diabetes mellitus. The oral form of AC-201 has been approved for treating chronic rheumatic diseases in France and later in various European and Middle Eastern countries, including Spain and Italy, since the mid-1990s.
The anticipated launch of these emerging therapies are poised to transform the epidermolysis bullosa market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the epidermolysis bullosa market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about which new EB therapies have been approved recently @ Epidermolysis Bullosa Drugs
Recent Developments in the Epidermolysis Bullosa Market
What is Epidermolysis Bullosa?
Epidermolysis bullosa is a rare group of genetic disorders that makes the skin extremely fragile and prone to blistering from even minor friction or injury. Because the proteins that normally anchor the layers of skin together are missing or not working properly, the skin can split and form painful blisters with everyday activities like walking, holding objects, or rubbing clothing. Epidermolysis bullosa can range from mild forms that mainly affect the hands and feet to severe forms involving widespread blistering, internal complications, and significant medical needs. While there is currently no cure, supportive care, wound management, and emerging therapies aim to improve comfort and quality of life for those living with the condition.
Epidermolysis Bullosa Epidemiology Segmentation
The epidermolysis bullosa epidemiology section provides insights into the historical and current epidermolysis bullosa patient pool and forecasted trends for the leading markets. Across the 7MM (excluding the US), recessive DEB (RDEB) was more common than dominant DEB (DDEB).
The epidermolysis bullosa treatment market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets, segmented into:
Epidermolysis Bullosa Market Report Metrics
Details
Study Period
2020–2034
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Epidermolysis Bullosa Epidemiology Segmentation
Total Prevalent Cases of Epidermolysis Bullosa, Diagnosed Prevalent Cases of Epidermolysis Bullosa, Type-specific Cases of Epidermolysis Bullosa, Gender-specific Cases of Epidermolysis Bullosa, and Age-specific Cases of Epidermolysis Bullosa
Key Epidermolysis Bullosa Companies
Castle Creek Biosciences, RHEACELL, AOP Health, SHIONOGI, StemRIM, Krystal Biotech, Aegle Therapeutics, TWi Biotechnology, Chiesi, Japan Tissue Engineering, Abeona Therapeutics, and others
Key Epidermolysis Bullosa Therapies
D-Fi/FCX-007, EBESANAR, Redasemtide, KB803, AGLE-102, AC-203, VYJUVEK, FILSUVEZ, JACE, ZEVASKYN, and others
Scope of the Epidermolysis Bullosa Market Report
Download the report to understand which companies are driving growth in the epidermolysis bullosa market @ Epidermolysis Bullosa Market Analysis
Table of Contents
1
Epidermolysis Bullosa Market Key Insights
2
Epidermolysis Bullosa Market Report Introduction
3
Executive Summary of Epidermolysis Bullosa
4
Key Events
5
Epidemiology and Market Forecast Methodology
6
Epidermolysis Bullosa Market Overview at a Glance
6.1
Market Share (%) Distribution by Therapies in 2024
6.2
Market Share (%) Distribution by Therapies in 2034
7
Epidermolysis Bullosa: Disease Background and Overview
7.1
Introduction
7.2
Causes of Epidermolysis Bullosa
7.3
Signs and Symptoms of Epidermolysis Bullosa
7.4
Pathogenesis of Epidermolysis Bullosa
7.5
Pathophysiology of Itch in Epidermolysis Bullosa Skin
7.6
Classification of Epidermolysis Bullosa
7.7
Genetic Bases of Epidermolysis Bullosa
7.8
Diagnosis of Epidermolysis Bullosa
8
Treatment and Management of Epidermolysis Bullosa
9
Guidelines
10
Epidemiology and Patient Population of 7MM
10.1
Key Findings
10.2
Assumption and Rationale
10.3
Total Prevalent Cases of Epidermolysis Bullosa in the 7MM
10.4
Diagnosed Prevalent Cases of Epidermolysis Bullosa in the 7MM
10.5
The United States
10.5.1
Total Prevalent Cases of Epidermolysis Bullosa in the United States
10.5.2
Diagnosed Prevalent Cases of Epidermolysis Bullosa in the United States
10.5.3
Type-specific Cases of Epidermolysis Bullosa in the United States
10.5.4
Gender-specific Cases of Epidermolysis Bullosa in the United States
10.5.5
Age-specific Cases of Epidermolysis Bullosa in the United States
10.6
EU4 and the UK
10.7
Japan
11
Epidermolysis Bullosa Patient Journey
12
Marketed Epidermolysis Bullosa Drugs
12.1
Key Competitors
12.2
VYJUVEK (beremagene geperpavec): Krystal Biotech
12.2.1
Product Description
12.2.2
Regulatory Milestones
12.2.3
Other Developmental Activities
12.2.4
Clinical Developmental Activities
12.2.4.1
Clinical Trial Information
12.2.5
Safety and Efficacy
12.2.6
Analyst Views
12.3
FILSUVEZ (oleogel-S10): Chiesi
12.4
JACE (human epidermal cell sheet): Japan Tissue Engineering
12.5
ZEVASKYN: Abeona Therapeutics
13
Emerging Epidermolysis Bullosa Drugs
13.1
Key Competitors
13.2
D-Fi (dabocemagene autoficel): Castle Creek Biosciences
13.2.1
Product Description
13.2.2
Other Developmental Activities
13.2.3
Clinical Developmental Activities
13.2.3.1
Clinical Trial Information
13.2.4
Safety and Efficacy
13.2.5
Analyst Views
13.3
Redasemtide: Shionogi
13.4
KB803: Krystal Biotech
13.5
EBESANAR: RHEACELL and AOP Health
13.6
AGLE-102: Aegle Therapeutics
14
Epidermolysis Bullosa Market: 7MM Analysis
14.1
Key Findings
14.2
Epidermolysis Bullosa Market Outlook
14.3
Key Market Forecast Assumptions
14.4
Conjoint Analysis
14.5
Total Market Size of Epidermolysis Bullosa in the 7MM
14.6
United States Epidermolysis Bullosa Market Size
14.6.1
Total Market Size of Epidermolysis Bullosa in the United States
14.6.2
Market Size of Epidermolysis Bullosa by Therapies in the United States
14.7
EU4 and the UK Epidermolysis Bullosa Market Size
14.8
Japan Epidermolysis Bullosa Market Size
15
Epidermolysis Bullosa Market Unmet Needs
16
Epidermolysis Bullosa Market SWOT Analysis
17
KOL Views on Epidermolysis Bullosa
18
Epidermolysis Bullosa Market Access and Reimbursement
18.1
United States
18.2
EU4 and the UK
18.3
Japan
18.4
Epidermolysis Bullosa Market Access and Reimbursement
19
Bibliography
20
Epidermolysis Bullosa Market Report Methodology
Related Reports
Epidermolysis Bullosa Clinical Trial Analysis
Epidermolysis Bullosa Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key epidermolysis bullosa companies, including Abeona Therapeutics, InMed Pharmaceuticals, BioMendics, RHEACELL, Castle Creek Biosciences, BPGbio, Eloxx Pharmaceuticals, Phoenicis Therapeutics, Aegle Therapeutics, Amryt Pharma, among others.
Dystrophic Epidermolysis Bullosa Market
Dystrophic Epidermolysis Bullosa Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key DEB companies including Castle Creek Biosciences, Amryth Pharma, Krystal Biotech, Abeona Therapeutics, BridgeBio, Phoenix Tissue Repair, and others.
Atopic Dermatitis Market
Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key atopic dermatitis companies including Kyowa Kirin, Amgen, Sanofi, UNION Therapeutics, Biosion, LEO Pharma, Connect Biopharma, Nektar Therapeutics, Apogee Therapeutics, Roche, Genentech, Eli Lilly and Company, Almirall, Organon, Torii Pharmaceutical, Chugai Pharmaceutical, Galderma, Maruho, AbbVie, Pfizer, Regeneron Pharmaceuticals, Incyte, Japan Tobacco, Otsuka Pharmaceutical, Medimetriks Pharmaceuticals, Acrotech Biopharma, and others.
Moderate to Severe Atopic Dermatitis Market
Moderate to Severe Atopic Dermatitis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key moderate to severe atopic dermatitis companies, including Jiangsu Vcare Pharmaceutical Technology Co., LTD, Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd., Nektar Therapeutics, E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Corvus Pharmaceuticals, Inc., UCB Biopharma SRL, Tavotek Biotherapeutics, Guangdong Hengrui Pharmaceutical Co., Ltd, SCM Lifescience Co., LTD., Sanofi, Amgen, Qurient Co., Ltd., Sun Pharmaceutical Industries Limited, Pfizer, UNION therapeutics, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
SOURCE DelveInsight Business Research, LLP